The role of maintenance therapy in acute myeloid leukemia (AML) remains unclear. Continued therapy with cytotoxic agents similar to those used for induction and consolidation is associated with toxicity but can improve disease free survival (DFS). (
Disclosure:Research Funding: MGI Pharma. Honoraria Information: MGI Pharma. Membership Information: Member of advisory committees and speakers bureau - MGI Pharma. Off Label Use: Use of decitabine in remission. Use of decitabine in acute myeloid leukemia.